{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:08:14Z","timestamp":1790244494852,"version":"4.1.0"},"reference-count":149,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Incretin and multi-receptor agonist therapies have delivered the widest range of cardiometabolic benefit of any pharmacological class in a generation, with documented benefit across obesity, type 2 diabetes, cardiovascular and renal outcomes, heart failure with preserved ejection fraction, obstructive sleep apnea, and metabolic-dysfunction-associated steatohepatitis. A substantial fraction of the cardiovascular benefit is weight independent. The pivotal trial evidence is now mature, extending to the dedicated tirzepatide cardiovascular outcome program. The clinical and system-level processes that govern long-term cardiovascular and metabolic benefit, however, lie largely outside the efficacy envelope that these trials measure. Real-world persistence is approximately one-third at 12 months in non-diabetic obesity. Discontinuation is dominated by cost rather than therapeutic failure. Weight and cardiometabolic gains revert toward baseline within months of abrupt cessation. Cyclical use has emerged as a common real-world pattern among adults who discontinue and then restart therapy. Our review proposes a lifecycle framework that organizes the evidence along the patient journey from initiation through titration, on-treatment trajectory, adverse-event landscape, persistence, discontinuation, and reinitiation. Tirzepatide serves as the analytical center of gravity; the selective GLP-1 receptor agonist literature serves as the mature comparator. Seven analytical positions are advanced, and five specific trial designs are named as the research agenda the field requires, four of which remain unaddressed. The work ahead is to align trials, prescribing pathways, and access systems with the chronic-pharmacotherapy reality of the class.<\/jats:p>","DOI":"10.3389\/fendo.2026.1902185","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:23:12Z","timestamp":1790241792000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists"],"prefix":"10.3389","volume":"17","author":[{"given":"Syed Arman","family":"Rabbani","sequence":"first","affiliation":[{"name":"RAK Medical and Health Sciences University","place":["Ras Al Khaimah, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El-Tanani","sequence":"additional","affiliation":[{"name":"RAK Medical and Health Sciences University","place":["Ras Al Khaimah, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail I.","family":"Matalka","sequence":"additional","affiliation":[{"name":"RAK Medical and Health Sciences University","place":["Ras Al Khaimah, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Palermo","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"New Engl J Medicine"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03374-z","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nat Medicine"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"New Engl J Medicine"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"New Engl J Medicine"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"New Engl J Medicine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"New Engl J Medicine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"New Engl J Medicine"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23563","article-title":"Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: a systematic review and meta-analysis","volume":"30","author":"Sarma","year":"2022","journal-title":"Obesity"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.23332","article-title":"Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes","volume":"30","author":"Gleason","year":"2024","journal-title":"J Managed Care Specialty Pharmacy"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24331","article-title":"Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status","volume":"33","author":"Gasoyan","year":"2025","journal-title":"Obesity"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obesity Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13929","article-title":"Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: a systematic review and meta-analysis","volume":"26","author":"Berg","year":"2025","journal-title":"Obesity Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12933-023-01800-z","article-title":"Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study","volume":"22","author":"Piccini","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/oby.70058","article-title":"Reasons for discontinuation of obesity pharmacotherapy with semaglutide or tirzepatide in clinical practice","volume":"33","author":"Gasoyan","year":"2025","journal-title":"Obesity"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70535","article-title":"Real-world persistence and dose titration of GLP-1 receptor agonists in type 2 diabetes: a UK population-based cohort study by obesity and cardiovascular disease status","volume":"28","author":"Ulrich","year":"2026","journal-title":"Diabetes Obesity Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/OP.2025.21.10_suppl.193","article-title":"Disparities in access of GLP-1 receptor agonists in cancer patients with obesity or type 2 diabetes: a cascade-of-care analysis across the semaglutide shortage timeline","volume":"21","author":"Ashruf","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"B21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"New Engl J Medicine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24332","article-title":"Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial","volume":"33","author":"Lam","year":"2025","journal-title":"Obesity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"New Engl J Medicine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes Obesity Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Internal Medicine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06243-z","article-title":"Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study","volume":"67","author":"Hurtado","year":"2024","journal-title":"Diabetologia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Medicine"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI194740","article-title":"The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications","volume":"136","author":"Jalleh","year":"2026","journal-title":"J Clin Investigation"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05956-x","article-title":"Incretin hormones and type 2 diabetes","volume":"66","author":"Nauck","year":"2023","journal-title":"Diabetologia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2025.102118","article-title":"Glucose-dependent insulinotropic polypeptide (GIP)","volume":"95","author":"M\u00fcller","year":"2025","journal-title":"Mol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03774-9","article-title":"Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial","volume":"31","author":"Martin","year":"2025","journal-title":"Nat Medicine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14110","article-title":"The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists","volume":"22","author":"Urva","year":"2020","journal-title":"Diabetes Obesity Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae155","article-title":"Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility","volume":"166","author":"Jalleh","year":"2025","journal-title":"Endocrinology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqad028","article-title":"Enhanced endosomal signaling and desensitization of GLP-1R vs GIPR in pancreatic beta cells","volume":"164","author":"Manchanda","year":"2023","journal-title":"Endocrinology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"A4139912","DOI":"10.1161\/circ.150.suppl_1.4139912","article-title":"Abstract 4139912: Inflammatory biomarkers in people treated with tirzepatide living with overweight or obesity, without and with T2D: a post-hoc analysis from SURMOUNT-1 and SURMOUNT-2","volume":"150","author":"Sattar","year":"2024","journal-title":"Circulation"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","article-title":"Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Neeland","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41467-022-28683-0","article-title":"Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors","volume":"13","author":"Zhao","year":"2022","journal-title":"Nat Communications"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-023-00811-0","article-title":"The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets","volume":"5","author":"El","year":"2023","journal-title":"Nat Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101139","article-title":"Targeting the GIPR for obesity: to agonize or antagonize? Potential mechanisms","volume":"46","author":"Campbell","year":"2021","journal-title":"Mol Metab"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1038\/s41467-020-18751-8","article-title":"Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism","volume":"11","author":"Killion","year":"2020","journal-title":"Nat Communications"},{"key":"B46","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cmet.2024.11.003","article-title":"The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice","volume":"37","author":"Yu","year":"2025","journal-title":"Cell Metab"},{"key":"B47","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","article-title":"A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant","year":"2024","journal-title":"Nat Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"New Engl J Medicine"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101090","article-title":"Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease","volume":"46","author":"Baggio","year":"2021","journal-title":"Mol Metab"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","author":"Jalleh","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00226-8","article-title":"Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial","volume":"13","author":"Wharton","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1172\/JCI146353","article-title":"GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice","volume":"131","author":"Samms","year":"2021","journal-title":"J Clin Investigation"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"New Engl J Medicine"},{"key":"B58","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New Engl J Medicine"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New Engl J Medicine"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B62","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"New Engl J Medicine"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"New Engl J Medicine"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"New Engl J Medicine"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"New Engl J Medicine"},{"key":"B68","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"New Engl J Medicine"},{"key":"B69","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"New Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"New Engl J Medicine"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.06.001","article-title":"Efficacy of semaglutide by sex in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF trials","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.067505","article-title":"Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial","volume":"149","author":"Kosiborod","year":"2024","journal-title":"Circulation"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"New Engl J Medicine"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04071-1","article-title":"Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial","volume":"32","author":"Malhotra","year":"2026","journal-title":"Nat Medicine"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obesity"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"New Engl J Medicine"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Medicine"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"New Engl J Medicine"},{"key":"B83","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"New Engl J Medicine"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.125.074545","article-title":"Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial","volume":"151","author":"Marx","year":"2025","journal-title":"Circulation"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease\u00a0in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Medicine"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat Medicine"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of Care in Diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of Care in Diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"B91","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03052-0","article-title":"Effectiveness of bariatric metabolic surgery versus glucagon-like peptide-1 receptor agonists for prevention of congestive heart failure","volume":"30","author":"Wolff Sagy","year":"2024","journal-title":"Nat Medicine"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16176","article-title":"Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials","volume":"27","author":"Rubino","year":"2025","journal-title":"Diabetes Obesity Metab"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70004","article-title":"Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic","volume":"27","author":"Samuels","year":"2025","journal-title":"Diabetes Obesity Metab"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.13061","article-title":"Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: a post hoc analysis of the randomized, placebo-controlled SCALE teens trial","volume":"18","author":"Bensignor","year":"2023","journal-title":"Pediatr Obesity"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Internal Medicine"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Medicine"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat Medicine"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.4661","article-title":"GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease","volume":"184","author":"Kanwal","year":"2024","journal-title":"JAMA Internal Medicine"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"Look","year":"2025","journal-title":"Diabetes Obesity Metab"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00027-0","article-title":"Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial","volume":"13","author":"Sattar","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obesity Metab"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0062-9","article-title":"Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies","volume":"14","author":"Batsis","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-025-09967-4","article-title":"New drugs for the treatment of obesity: do we need approaches to preserve muscle mass","volume":"26","author":"Ryan","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-024-01473-y","article-title":"What is the pipeline for future medications for obesity","volume":"49","author":"Melson","year":"2025","journal-title":"Int J Obesity"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12926","article-title":"Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials","volume":"19","author":"Monami","year":"2017","journal-title":"Diabetes Obesity Metab"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-25-02237","article-title":"Risk for cancer with glucagon-like peptide-1 receptor agonists and dual agonists: a systematic review and meta-analysis","volume":"179","author":"Ko","year":"2026","journal-title":"Ann Internal Medicine"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-0154","article-title":"Risk of thyroid tumors with GLP-1 receptor agonists: a retrospective cohort study","volume":"48","author":"Morales","year":"2025","journal-title":"Diabetes Care"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae722","article-title":"Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists","volume":"110","author":"Kelly","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.6555","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy","volume":"143","author":"Cai","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16316","article-title":"Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish-Norwegian cohort study","volume":"27","author":"Simonsen","year":"2025","journal-title":"Diabetes Obesity Metab"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.26327","article-title":"Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes","volume":"8","author":"Wang","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15872","article-title":"Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: a nationwide registry study","volume":"26","author":"Lassen","year":"2024","journal-title":"Diabetes Obesity Metab"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes","volume":"7","author":"Do","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obesity"},{"key":"B120","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s12933-025-02915-1","article-title":"Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes","volume":"24","author":"S\u00f8rensen","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions","volume":"86","author":"Moiz","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000004776","article-title":"ASA consensus-based guidance on preoperative management of patients on glucagon-like peptide-1 receptor agonists","volume":"140","author":"Ushakumari","year":"2024","journal-title":"Anesthesiology"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1111\/anae.16601","article-title":"Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis","volume":"80","author":"Castrillon","year":"2025","journal-title":"Anaesthesia"},{"key":"B124","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.cgh.2024.07.021","article-title":"Effects of glucagon-like peptide-1 receptor agonists on upper gastrointestinal endoscopy: a meta-analysis","volume":"23","author":"Facciorusso","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000007764","article-title":"Assessment of gastric content using gastric ultrasound in patients on glucagon-like peptide-1 receptor agonists before anesthesia","volume":"142","author":"Pai","year":"2026","journal-title":"Anesthesia Analgesia"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-024-11263-2","article-title":"Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period","volume":"39","author":"Kindel","year":"2025","journal-title":"Surg Endoscopy"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407379","article-title":"Liraglutide for children 6 to <12 years of age with obesity - a randomized trial","volume":"392","author":"Fox","year":"2025","journal-title":"New Engl J Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16466","article-title":"Long-term cost-effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity","volume":"27","author":"Tang","year":"2025","journal-title":"Diabetes Obesity Metab"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment","volume":"393","author":"Wharton","year":"2025","journal-title":"New Engl J Medicine"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02165-8","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial","volume":"406","author":"Horn","year":"2025","journal-title":"Lancet"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505669","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes","volume":"393","author":"Rosenstock","year":"2025","journal-title":"New Engl J Medicine"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"New Engl J Medicine"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.06.003","article-title":"Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon\/glucagon-like peptide-1 receptor dual agonist, in cirrhosis","volume":"81","author":"Lawitz","year":"2024","journal-title":"J Hepatol"},{"key":"B135","unstructured":"ClinicalTrials.gov\n          LIVERAGE\u2122: A study to test whether survodutide helps people with a liver disease called NASH\/MASH who have moderate or advanced liver fibrosis"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.2337\/db24-262-OR","article-title":"262-OR: Pemvidutide, a GLP-1\/glucagon dual receptor agonist, in subjects with overweight or obesity - a 48-week, placebo-controlled, phase 2 (MOMENTUM) trial","volume":"73","author":"Aronne","year":"2024","journal-title":"Diabetes"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101691","article-title":"Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial","volume":"54","author":"Ji","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"New Engl J Medicine"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2504214","article-title":"Once-monthly maridebart cafraglutide for the treatment of obesity - a phase 2 trial","volume":"393","author":"Jastreboff","year":"2025","journal-title":"New Engl J Medicine"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1093\/milmed\/usaf522","article-title":"Semaglutide decreases risk of non-arteritic anterior ischemic optic neuroapthy in type 2 diabetic patients","volume":"191","author":"Lieberman","year":"2026","journal-title":"Military Med"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"New Engl J Medicine"},{"key":"B142","unstructured":"Silver Spring MD\n          U.S. Food and Drug Administration\n          FDA approves treatment for serious liver disease known as 'MASH'\n          \n          2025"},{"key":"B143","unstructured":"Bagsv\u00e6rd\n          Novo Nordisk A\/S\n          CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved. Company announcement\n          \n          2026"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S008","article-title":"8. Obesity and weight management for the prevention and treatment of diabetes: Standards of Care in Diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"B146","unstructured":"ClinicalTrials.gov\n          LIVERAGE\u2122 - Cirrhosis: A study to test whether survodutide helps people with a liver disease called NASH\/MASH who have cirrhosis"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70141","article-title":"Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study","volume":"28","author":"Alissou","year":"2026","journal-title":"Diabetes Obesity Metab"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.0905","article-title":"Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity","volume":"6","author":"Hwang","year":"2025","journal-title":"JAMA Health Forum"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1700894","article-title":"Mediterranean diet adherence and tirzepatide: real-world evidence on adiposity indices and insulin resistance beyond weight loss","volume":"16","author":"Patern\u00f2","year":"2026","journal-title":"Front Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1902185\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:23:14Z","timestamp":1790241794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1902185\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":149,"alternative-id":["10.3389\/fendo.2026.1902185"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1902185","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1902185"}}